166
Participants
Start Date
June 24, 2014
Primary Completion Date
November 15, 2016
Study Completion Date
December 12, 2016
Molidustat (BAY85-3934)
BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
Darbepoetin
Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
Budapest
Sofia
Sofia
Sofia
Sofia
Gosford
Esztergom
Melbourne
Reservoir
Montana
Debrecen
Karlovo
Pazardzhik
Veliko Tarnovo
Gabrovo
Lovech
Stara Zagora
Baja
Kaposvár
Pécs
Szigetvár
Burgas
Dobrich
Berlin
Córdoba
Santiago de Compostela
Milan
Milan
Lecco
Brescia
Cremona
Pavia
Madrid
Madrid
San Sebastián de los Reyes
Brest
Grenoble
Düsseldorf
Modena
Wuppertal
Bonn
Livorno
Valenciennes
Chieti
Pirmasens
Pierre-Bénite
Villingen-Schwenningen
Napoli
Limoges Cedex1
Oradea
Brasov
Târgu Mureş
Constanța
Nahariya
Hadera
Kfar Saba
Ashkelon
Jerusalem
Halle
Kitakyushu
Ōkawa
Muroran
Hakusan
Morioka
Fujisawa
Kamakura
Kuwana
Chiba
Fukuoka
Nagano
Nara
Bialystok
Poznan
Radom
Szczecin
Żyrardów
Bucharest
Bucharest
Bucharest
Bucheon-si
Seoul
Seoul
Seoul
L'Hospitalet de Llobregat
Alicante
Barcelona
Barcelona
Ankara Univ. Medical Faculty, Ankara
Baskent University Medical Faculty, Ankara
Sifa University Medical Faculty, Izmir
Reading
Cambridge
Dundee
Brighton
Salford
Hexham
Doncaster
Leeds
Chorley
Glasgow
Liverpool
Liverpool
London
London
Manchester
Lead Sponsor
Bayer
INDUSTRY